Viridian Therapeutics
VRDN
33 hedge funds and large institutions have $7.95M invested in Viridian Therapeutics in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 15 reducing their positions, and 17 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.29% less ownership
Funds ownership: 2.63% → 2.33% (-0.29%)
28% less funds holding
Funds holding: 46 → 33 (-13)
68% less capital invested
Capital invested by funds: $25M → $7.95M (-$17.1M)
76% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 17
80% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$49.3K |
| 2 |
Renaissance Technologies
New York
|
+$35.7K |
| 3 |
SAM
Seelaus Asset Management
Chatham,
New Jersey
|
+$25.3K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
+$11.4K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$5.84K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$399K |
| 2 |
MFAM
Motley Fool Asset Management
Alexandria,
Virginia
|
-$363K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$316K |
| 4 |
Millennium Management
New York
|
-$286K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$239K |
VRDN Hedge Fund Activity: Q3 2019 in Review
33 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q3 2019, worth a combined $7.95M — down 68% from $25M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of VRDN and 4 opened new positions — a net loss of 13 holders — while 15 trimmed existing stakes and 3 added.
The largest buyer was Vanguard Group, adding an estimated $49.3K. The largest seller was Goldman Sachs, cutting an estimated $399K.
- 33 institutional investors held Viridian Therapeutics (VRDN) as of Q3 2019, down from 46 in Q2 2019.
- Funds reported $7.95M of Viridian Therapeutics stock for Q3 2019, down 68% quarter-over-quarter.
- 4 funds opened new Viridian Therapeutics positions in Q3 2019 and 17 closed out, a net change of -13 holders.
- The largest Viridian Therapeutics buyer in Q3 2019 was Vanguard Group, an estimated $49.3K added.
- The largest Viridian Therapeutics seller in Q3 2019 was Goldman Sachs, an estimated $399K sold.
Based on aggregated 13F filings for Q3 2019.